Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35923923/
1 Susan F. Smith Center for Women's Cancers, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, Boston, MA, USA. 2 Breast Tumor Immunology Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA. 3...
Conclusions: In patients with HER2-positive IBC treated with neoadjuvant HP and paclitaxel for 16 weeks, gene expression patterns of tumor biopsies measured 1 week after treatment initiation not only offered different biological information but importantly served as a better predictor of pCR than baseline transcriptional analysis.
-
Sarah Mougalian, Yale Cancer Center3yrAlways good to add to the arsenal of biomarker information that can predict benefit/response from certain treatments.
Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report
Source : https://www.wjgnet.com/2307-8960/full/v10/i17/5923.htm
The Human epidermal receptor-2 (HER-2) gene is over-expressed in approximately 15%-20% of primary breast cancers, and HER-2-targeted therapies are associated with significantly improved survival. Neoadjuvant treatment (NAT) is the standard...
Core Tip: We presented a case diagnosed with the human epidermal receptor(HER)-2 breast cancer patient who exhibited changes in the expression of HER-2 receptors on tumour samples from surgical specimens obtained after neoadjuvant treatment (NAT) compared with initial biopsy. Changes in HER-2 expression after NAT should be retested by...
-
Sarah Mougalian, Yale Cancer Center3yrExcept that these patients would have been included in KATHERINE (which did not include repeat HER2 testing after neoadjuvant therapy and surgery), and particularly now given DESTINY-Breast04 findings, raises the Show More
Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysis - Supportive Care in Cancer
Source : https://link.springer.com/article/10.1007/s00520-022-07320-y
Aim The combination of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors plus endocrine therapy (ET) improved the survival outcomes and became the standard of care in the treatment of...
Conclusion: In this meta-analysis, we observed that adding CDK4/6 inhibitors to ET significantly increased the risk of all grade, grade 3 or higher infections, and urinary tract infections. We propose that closer follow-up for infections should be considered for metastatic breast cancer patients using CDK 4/6 inhibitors. This may help...
-
Sarah Mougalian, Yale Cancer Center3yrInteresting to see meta-analysis data from the major ribociclib, palbociclib, and abemaciclib trials regarding grade 3 or higher infections. We know that these agents cause neutropenia, but infections are much Show More
Second-Degree Type 2 Atrioventricular Block Requiring Permanent Cardiac Pacing in Patients on CDK4/6 Inhibitors: Report of Two Cases - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35957944/
To our knowledge, these are the first cases reported in the literature of new-onset advanced AV blocks in patients under treatment with CDK4/6Is, suggesting the clinical relevance of a more...
Conclusion: To our knowledge, these are the first cases reported in the literature of new-onset advanced AV blocks in patients under treatment with CDK4/6Is, suggesting the clinical relevance of a more frequent ECG monitoring, besides the QT interval, in these patients.
-
Sarah Mougalian, Yale Cancer Center3yr[~Albert--Dekker--aldekker@ ] I think we don't know that it is a causative association--but as abemaciclib carries an adjuvant indication (and heavy marketing presence on TV!) and ribociclib has demonstrated overall Show More
-
Albert Dekker4yrhow we know it is from CK4/6 and not from whatever other reason?
Cost-Effectiveness Analysis of Abemaciclib plus Fulvestrant versus Placebo plus Fulvestrant in Patients with Hormone Receptor-Positive, ERBB2-Negative Breast Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35957949/
1 Ward of General Practice/International Medical Center, West China Hospital, Sichuan University, Chengdu, China. 2 Department of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, China. 3 Department of Medical...
Conclusion: Despite significant gains in PFS over AF, it is not a cost-effective treatment for HR , HER2− ABC in the USA at current drug prices.
-
Sarah Mougalian, Yale Cancer Center3yrIn the text of the paper, the authors also looked at cost effectiveness of the abemaciclib/fulvestrant combination in Italy and Germany compared to placebo/fulvestrant, and they found that ICER was Show More